SpartaLabs
0
SpartaLabs Research · June 17, 2026

Kisspeptin-10: A Research Overview

An educational reference overview of kisspeptin-10 (KP-10) — its chemical identity, classification as an RF-amide neuropeptide, and KISS1R pharmacology. Educational reference.

kisspeptin-10kiss1rgpr54rf-amidegnrh-axis

Introduction

Kisspeptin-10 (KP-10) is a biologically active decapeptide derived from the C-terminal region of the KISS1 gene product, a protein classified in the RF-amide neuropeptide family. It is the minimal kisspeptin fragment that retains full agonist activity at the kisspeptin receptor (KISS1R, formerly designated GPR54) and is the subject of substantial published research into hypothalamic–pituitary–gonadal (HPG) axis signaling. This article provides an educational reference overview of KP-10's chemical identity, pharmacological classification, and historical context of discovery based on primary peer-reviewed literature.

Background

The KISS1 gene was originally identified in 1996 as a metastasis suppressor gene in melanoma cell lines, with the gene designation chosen partly to acknowledge its discovery in Hershey, Pennsylvania [1]. The gene's physiological reach proved considerably broader than cancer biology: in 2001, three independent research groups — Ohtaki et al., Kotani et al., and Muir et al. — simultaneously identified kisspeptins as the endogenous ligands for the then-orphan G-protein coupled receptor GPR54 [2, 3].

The functional significance of this ligand–receptor pair was established by two landmark clinical genetic studies published in 2003. Seminara and colleagues, reporting in the New England Journal of Medicine, demonstrated that loss-of-function mutations in GPR54 impair pubertal development in humans, placing the kisspeptin–KISS1R axis at the center of reproductive endocrinology research [4]. Concurrently, de Roux and colleagues reported GPR54 inactivating mutations in an inbred family with disrupted pubertal development, published in the Proceedings of the National Academy of Sciences [5]. Together, these reports generated a highly productive research program into KISS1R pharmacology that continues to the present.

Chemistry and Structure

The full-length KISS1 gene product is a 145-amino acid prepropeptide. Proteolytic processing in vivo yields several biologically active fragments, designated by their amino acid lengths: kisspeptin-54 (KP-54, also called metastin), kisspeptin-14 (KP-14), kisspeptin-13 (KP-13), and kisspeptin-10 (KP-10). All share a common C-terminal decapeptide sequence with a C-terminal amide group [6].

KP-10 corresponds to the amino acid sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ — the minimal active fragment of the KISS1 precursor. Structure-activity relationship studies have identified a pharmacophore consisting of Phe-6, Arg-9, and Phe-10-NH₂ as the residues primarily responsible for KISS1R binding [7]. The C-terminal amide group (–NH₂) is particularly important: removal of the amide substantially attenuates receptor binding affinity, and NMR-restrained molecular modeling indicates that KP-10 adopts a helicoidal conformation between residues Asn-4 and Tyr-10, with mixed alpha- and 3(10)-helix character [7].

KP-10 belongs to the broader RF-amide peptide family, a class of neuropeptides defined by a conserved C-terminal Arg-Phe-NH₂ motif. Its molecular weight is approximately 1,302 daltons. Pharmacokinetic studies in rats reported a plasma half-life of approximately four minutes following intravenous administration, reflecting rapid enzymatic degradation — a property that has informed development of KP-10 analogs with extended bioactivity [8].

Pharmacological Classification

KP-10 is classified as a full agonist at KISS1R, a class A G-protein-coupled receptor that signals primarily through the Gq/11 pathway. The International Union of Basic and Clinical Pharmacology (IUPHAR) formally recommended the designation "kisspeptin receptor" for GPR54 in 2010, following the convention of naming receptors after their endogenous ligand [6]. The gene was correspondingly renamed KISS1R.

Within the broader pharmacological landscape, KP-10 and the other kisspeptin isoforms are the only known endogenous ligands for KISS1R — a signaling distinction shared with closely related hypothalamic peptides such as oxytocin acetate, another GPCR-targeted neuropeptide active in hypothalamic neuroendocrine circuits. The receptor is widely expressed in the hypothalamus, pituitary, and peripheral tissues including placenta, ovary, and testis. Its hypothalamic expression on gonadotropin-releasing hormone (GnRH) neurons is the basis for KP-10's reported activity in HPG axis signaling, as characterized in published research [9].

Regulatory and Research Status

KP-10 is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any therapeutic indication, nor is it listed as a scheduled controlled substance under the US Controlled Substances Act. Research involving kisspeptin isoforms, including KP-10, has been conducted under Investigational New Drug (IND) applications and equivalent regulatory frameworks in the UK and Europe.

Clinical research programs at institutions including Imperial College London have administered kisspeptin isoforms to healthy volunteers and defined research populations in ethics-approved trial settings [10]. The active investigational research program — spanning controlled human neuroendocrine studies, analog development, and KNDy circuitry investigations — reflects the scientific community's sustained interest in KISS1R pharmacology as a research tool.

As a research-use-only compound, kisspeptin-10 from SpartaLabs is studied in laboratory settings under applicable institutional and regulatory guidelines governing research with peptide materials.

Discovery History

The discovery of KP-10 as a distinct bioactive fragment emerged from the convergence of two independent lines of research: cancer biology and neuroendocrinology. The KISS1 gene was first cloned in 1996 by Lee and colleagues, who identified it as a metastasis suppressor in chromosome 6/melanoma hybrid cell experiments at Penn State College of Medicine [1].

The pivotal identification of kisspeptins as GPR54 ligands in 2001 opened a new chapter. Ohtaki and colleagues at Takeda Chemical Industries reported in Nature that the gene product — which they initially termed "metastin" — was the endogenous ligand for GPR54, a previously orphan receptor [2]. Kotani et al. and Muir et al. published parallel characterizations within weeks, establishing the receptor–ligand pair now known as KISS1R–kisspeptin from independent discovery approaches [3].

Recognition that KP-10 — the smallest KISS1 cleavage product — retained full receptor agonist activity was significant for pharmacological research, as it offered a tractable scaffold for analog development and mechanistic studies; synthesis and verification standards for KP-10 as a research compound are detailed in the companion sourcing and quality article. Published structure-activity work through the late 2000s characterized the binding pharmacophore and led to development of both agonist analogs and peptide antagonists, enabling researchers to probe KISS1R's physiological roles with precision [7].

References

  1. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88(23):1731-1737. PMID: 8944003. DOI: 10.1093/jnci/88.23.1731

  2. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613-617. PMID: 11385580. DOI: 10.1038/35079135

  3. Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. PMID: 11457843. DOI: 10.1074/jbc.M104847200

  4. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. PMID: 14573733. DOI: 10.1056/NEJMoa035322

  5. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA. 2003;100(19):10972-10976. PMID: 12944565. DOI: 10.1073/pnas.1834399100

  6. Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev. 2012;92(3):1235-1316. PMID: 22811428. DOI: 10.1152/physrev.00037.2010

  7. Niida A, Wang Z, Tomita K, Oishi S, Tamamura H, Otaka A, et al. Design and synthesis of downsized metastin (45–54) analogs with maintenance of high GPR54 agonistic activity. Bioorg Med Chem Lett. 2006;16(1):134-137. PMID: 16214345. DOI: 10.1016/j.bmcl.2005.09.054

  8. Liu Z, Ren C, Jones W, Chen P, Seminara SB, Chan YM, et al. LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;926:1-8. PMID: 23524040. DOI: 10.1016/j.jchromb.2013.02.027

  9. Colledge WH. Kisspeptins and GnRH neuronal signalling. Trends Endocrinol Metab. 2009;20(3):115-121. PMID: 19272794. DOI: 10.1016/j.tem.2008.10.005

  10. Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewski A, Vaal ML, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(8):E1299-E1307. PMID: 21632807. DOI: 10.1210/jc.2011-0231

Frequently asked questions

  • What is kisspeptin-10?

    Kisspeptin-10 (KP-10) is a biologically active decapeptide derived from the C-terminal region of the KISS1 gene product. It is the minimal kisspeptin fragment that retains full agonist activity at the kisspeptin receptor (KISS1R, formerly GPR54) and is classified within the RF-amide neuropeptide family.

  • What is the chemical structure of kisspeptin-10?

    KP-10 corresponds to the amino acid sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, with a molecular weight of approximately 1,302 daltons. Structure-activity relationship studies have identified Phe-6, Arg-9, and the C-terminal Phe-10-NH₂ as the residues primarily responsible for KISS1R binding.

  • Is kisspeptin-10 FDA approved?

    Kisspeptin-10 is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any therapeutic indication, nor is it listed as a scheduled controlled substance under the US Controlled Substances Act. It is studied as a research-use-only compound under applicable institutional and regulatory guidelines.

  • Who discovered kisspeptin-10?

    The KISS1 gene was first cloned in 1996 by Lee and colleagues at Penn State College of Medicine. The identification of kisspeptins — including the KP-10 fragment — as the endogenous ligands for the orphan receptor GPR54 was simultaneously reported in 2001 by three independent groups: Ohtaki et al., Kotani et al., and Muir et al.

  • What receptor does kisspeptin-10 target?

    Kisspeptin-10 is a full agonist at KISS1R (formerly GPR54), a class A G-protein-coupled receptor that signals primarily through the Gq/11 pathway. KISS1R is the only known receptor for kisspeptin peptides and is widely expressed in the hypothalamus, pituitary, and peripheral tissues.